

Inogen Inc  
Form 8-K/A  
March 31, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**March 27, 2014**

**INOGEN, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36309**  
**(Commission**  
  
**File Number)**

**33-0989359**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: Inogen Inc - Form 8-K/A

**326 Bollay Drive**

**Goleta, California**

**(Address of principal executive offices, including zip code)**

**(805) 562-0500**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Explanatory Note**

*This report amends our Current Report on Form 8-K filed on March 27, 2014. The amended and restated disclosure is set forth below.*

**Item 2.02. Results of Operations and Financial Condition.**

The information in this Current Report on Form 8-K is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On March 27, 2014, Inogen, Inc. issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2013. A copy of the press release was furnished as Exhibit 99.1 to our Current Report on Form 8-K. The press release furnished in the prior version of this Form 8-K referenced net income, including the one-time tax asset benefit attributable to common stockholders for the year ended December 31, 2013, was \$18.2 million, or \$1.10 per diluted common share, compared with (\$5.2) million, or (\$19.97) loss per diluted common share, for the 2012 period. The prior disclosure should have referenced \$0.68 per diluted common share for the year ended December 31, 2013. The press release furnished in the prior version of this Form 8-K also referenced net income, including the one-time tax asset benefit attributable to common stockholders for the three months ended December 31, 2013, was \$20.1 million, or \$0.79 per diluted common share, compared with (\$1.6) million, or (\$5.71) loss per diluted common share, for the comparative 2012 period. The prior disclosure should have referenced \$1.11 per diluted common share for the three months ended December 31, 2013. The changes in per diluted common share numbers are a result of a recalculation of the deemed dividend amount allocated to the holders of preferred stock. The corrected per diluted common share numbers are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2014.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit</b>	<b>Description</b>
99.1	Inogen, Inc. Press Release, dated March 27, 2014. *

\* Previously filed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INOGEN, INC.**

By: /s/ Alison Bauerlein  
Alison Bauerlein

Executive Vice President, Finance, Chief  
Financial Officer, Secretary and Treasurer

Date: March 31, 2014

**EXHIBIT INDEX**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Inogen, Inc. Press Release, dated March 27, 2014. *

\* Previously filed.